Imclone--hier hilft wohl nur ein Call

und heute gehts weiter nach oben!

StreetInsider Alert for IMCL  


May 13, 2004 (streetinsider.com via COMTEX) -- Oppenheimer initiates coverage
on Imclone (Nasdaq: IMCL) with a 'buy' rating and $84 price target


Aktuell bei 72,85 $

Habe heute 20 % versäumt, weil ich sicherheitshalber heute vor Börsenbeginn verkauft hatte, weil die Vorbörse im Minus war von Imclone!

Da ich mit 20 % im Plus war, habe ich den Gewinn eben mitgenommen. Ging jetzt tgl. seitwärts, und heute gehst aufwärts, weil alle runter gingen!

ein SL hätte es heute auch nicht gebracht, weil es Anfagngs leicht nach unten ging, und da wäre ich dann ausgestoppt worden!

Cést la vie!

wurden ja nur gute sachen gesagt. und für sonntag abend neue forschungs-ergebnisse angekündigt. erstaunlich, dass die aktie in diesem zusammenhang noch nicht reagiert. wens interessiert : sonntag abend live auf deren homepage (investor relation, dann presentation). kann eigentlich nur gutes kommen, wird spannend !

Mal hören, was IMCL auf der Konferenz so sagt. Aber ich denke, die Aktie geht weiter Richtung 100,-- US Dollar.

Ciao B.L.

erbitux wirkt nicht nur bei darmkrebs, sondern auch sensationelle test-ergebnisse bei head- and neck cancer. und da das medikament ja schon die zulassung (für darmkrebs) hat, dürfte die neue zulassung extrem zügig gehen !! viel hoffnung für die patienten. unter anderem verdoppelung (!) der lebenserwartung !!!!
zusätzliches bonbon für die aktionäre: mit dieser baldigen neuen zulassung dürfte dann auch (laut der pressemitteilung vom 1.6.) 350 mio $ weiteres milestone payment von bristol meyers fällig werden.

ir.thomsonfn.com/InvestorRelations/...tner=4918&storyId=115380

  81.350  
+8.860  +12.22%  


Daily Commentary  

    WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 6/2/2004 (5) days ago, when the stock price was 74.850. Since then the stock gained 8.68% .  

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. A bullish gap occured, which may indicate an upward break out.The volume is extremely high. The security price is trending up and is overbought.



Click here to get a full trend analysis of this stock   Candlestick Analysis  
           

Today’s Candlestick Patterns:
High Wave


Today a High Wave formed. Both the bulls and the bears were active during the session, and the volume was high. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates that the market may be losing its direction and a change in trend may be imminent!

RV (Relative Value): RV is an indicator of long-term price appreciation potential. IMCL has an RV of 0.89, which is fair on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.
 
RS (Relative Safety): RS is an indicator of risk. IMCL has an RS rating of 0.71, which is poor on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.
 
RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. IMCL has a Relative Timing rating of 1.79, which is excellent on a scale of 0.00 to 2.00.  RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.  
 
VST (VST-Vector):  VST is the master indicator for ranking every stock in the VectorVest database. IMCL has a VST rating of 1.28, which is very good on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price. The efficacy of this indicator was demonstrated in a study conducted at the University of Chicago which showed that high VST stocks outperformed the S&P 500 by 583.1% over the six year period from 1996 through 2002.  
 
CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. IMCL has a CI rating of 0.86, which is fair on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.  
 
GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. IMCL has a forcasted Earnings Growth Rate of 31.00%, which VectorVest considers to be excellent. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (8.41%).  
 
Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. IMCL has a Buy recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.  
 
Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position.  IMCL has a Stop of $67.43 per share. This is $13.95 below IMCL's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.
 
EPS (Earnings per Share):  EPS stands for leading 12 months Earnings Per Share.  IMCL has a forecasted EPS of $1.20 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.  
 
P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings.  IMCL has a P/E of 67.82. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 33.60. P/E is computed daily using the formula: P/E = Price/EPS.  
 
EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. IMCL has an EY of 1.48 percent. This is below the current average of 2.97% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).  
 
GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. IMCL has a GPE rating of 0.46.  High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 6.11%, the operative GPE ratio is 0.37. Therefore, IMCL may be considered to be undervalued.  
 
DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. IMCL does not pay a dividend.  
 
DY (Dividend Yield): DY reflects earnings per share as a percent of Price. IMCL does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.  
 
DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. IMCL does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.

 
DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. IMCL does not pay a dividend, so it does not have a Dividend Growth rating .  
 
YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. IMCL does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.  
 
Open: IMCL opened trading at a price of $81.38 per share on 6/7/2004.
 
High: IMCL traded at a High price of $82.19 per share on 6/7/2004.
 
Low: IMCL traded at a Low price of $77.11 per share on 6/7/2004
 
Close: IMCL closed trading at price $81.38 per share on 6/7/2004. (Close is also called Price in the VectorVest system)
 
Range: Range reflects the difference between the High and Low prices for the day. IMCL traded with a range of $5.08 per share on 6/7/2004.  
 
$Change: IMCL closed up 8.89 from the prior day's closing Price.  
 
%PRC: IMCL's Price changed 12.26% from the prior day's closing price.
 
Volume: IMCL traded 19,546,000 shares on 6/7/2004.
 
AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. IMCL has an AvgVol of 3,691,000 shares traded per day.
 
%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals 100 x (Volume/AvgVol). IMCL had a %Vol of 429.56% on 6/7/2004
 
Sales: IMCL has annual sales of $170,000,000
 
Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. IMCL has a Sales Growth of 460.00% per year. This is excellent. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.  
 
Sales Per Share (SPS): IMCL has annual sales of $2.26 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.  
 
Price to Sales Ratio (P/S): IMCL has a P/S of 36.00. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.
 
Shares: IMCL has 75,000,000 shares of stock outstanding.
 
Market Capitalization: IMCL has a Market Capitalization of $6,151,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.
 
Industry Group: IMCL has been assigned to the Drug (Biomedical\Genetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
 
Business Sector: IMCL has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
 
The basic strategy of VectorVest is to buy Low risk, High reward stocks. We suggest that Prudent investors buy enough High Relative Value, High Relative Safety stocks to keep the overall RV and RS ratings of their portfolios above 1.00. As you do this, you'll find that your risk will go down and your investment performance will improve.
 
 
Graph
 
Imclone Sys
 
 
Drug (Biomedical\Genetic)
 
 






 

www.asco.org/ac/1,1003,_12-002546,00.asp?Search=ImClone

Composite Indicator  
  Trend Spotter (TM) Buy  
 
Short Term Indicators  
  7 Day Average Directional Indicator Buy  
  10 - 8 Day Moving Average Hilo Channel Buy  
  20 Day Moving Average vs Price Buy  
  20 - 50 Day MACD Oscillator Buy  
  20 Day Bollinger Bands Buy  
 
Short Term Indicators Average:   100% - Buy
20-Day Average Volume - 3809530
 
Medium Term Indicators  
  40 Day Commodity Channel Index Buy  
  50 Day Moving Average vs Price Buy  
  20 - 100 Day MACD Oscillator Buy  
  50 Day Parabolic Time/Price Buy  
 
Medium Term Indicators Average:   100% - Buy
50-Day Average Volume - 3717458
 
Long Term Indicators  
  60 Day Commodity Channel Index Buy  
  100 Day Moving Average vs Price Buy  
  50 - 100 Day MACD Oscillator Buy  
 
Long Term Indicators Average:   100% - Buy
100-Day Average Volume - 3059231
 
Overall Average:   100% - Buy
 
Price  Support  Pivot Point  Resistance  

81.38  75.15  80.23  85.31  


Click on the indicator for a graphical interpretation of the result
or visit the Learning Center for more information on the studies



Subscription benefits include the ability to search through all technical analysis featured on the site

mal nicht so früh verkauft, habe nur 5 Cent je schein verdient, hätten über 1 Euro sein können :-((

Gestern war Imclone bei den Dollar Gewinnern, und Plus 3,21

Ich habe den Call langfristig gewählt und im Geld Basis 60 $ Laufzeit Nov. Kauf 7.6. zu 21.90 a 100 Stück.
Es gibt vergleichbare OS.

was defined as partial response (12.6%) plus stable disease (33%). Median time
to progression was 2.3 months, median survival was 5.9 months, and median
duration of response was 5.9 months.

In 53 patients whose disease progressed during ERBITUX monotherapy who then
received ERBITUX in combination with platinum-based chemotherapy, there were 14
patients with stable disease, 14 patients with progressive disease and 25
patients were not assessable. Median time to progression in this group was 50
days.

The most commonly reported adverse events occurring in more than 20 percent of
patients, regardless of relationship to therapy, included acne-like rash (69%;
grade 3/4, 1%) and fatigue (24%; grade 3/4, 4%). Additional grade 3/4 adverse
events included vomiting (2%), nausea (1%) and diarrhea (1%). There was one
treatment-related death due to infusion reaction.

Abstract #5513

A randomized phase I study conducted by Merck KGaA (EMR-008) evaluated the
safety and tolerability of ERBITUX in combination with one of three doses of
5-FU and either cisplatin or carboplatin in 53 patients with recurrent and/or
metastatic SCCHN.

An efficacy analysis of the pooled arms demonstrated a disease control rate of
69.8 percent (95% CI: 55.7-81.7), which was defined as complete response plus
partial response plus stable disease. The overall response rate was 35.9 percent
(95% CI: 23.1-50.2). Median time to progression was 155 days (95% CI: 127-186),
and median survival was 297 days (95% CI: 242-418).

The most frequent adverse event (any grade) was skin reaction (74%, cisplatin
group; 92%, carboplatin group). The most frequent grade 3/4 adverse events in
the group receiving cisplatin (n=27) regardless of relationship to study
medication were leucopenia (56%), asthenia (33%), nausea/vomiting (26%),
mucositis (15%), anemia (15%), thrombocytopenia (11%), diarrhea (7%) and
anorexia (4%). Among patients receiving carboplatin (n=25), the most frequent
grade 3/4 adverse events regardless of relationship to study medication were
leucopenia (20%), thrombocytopenia (20%), asthenia (16%), mucositis (12%),
anemia (8%), acne-like reaction (4%) and skin reaction (4%).

ERBITUX(TM) (Cetuximab) Approved Indication

ERBITUX is approved by the FDA for use in combination with irinotecan in the
treatment of patients with EGFR-expressing, metastatic colorectal cancer who are
refractory to irinotecan-based chemotherapy and for use as a single agent in the
treatment of patients with EGFR-expressing, metastatic colorectal cancer who are
intolerant to irinotecan-based chemotherapy. The effectiveness of ERBITUX for
the treatment of colorectal cancer is based on objective response rates.
Currently, no data are available that demonstrate an improvement in
disease-related symptoms or increased survival with ERBITUX.

Outside the U.S., Merck KGaA, Darmstadt, Germany, gained approval for use of
ERBITUX in combination with irinotecan in patients with EGFR-expressing
metastatic colorectal cancer who have failed prior irinotecan therapy in
Switzerland in December 2003, with EU approval expected in June 2004.

In May 2004, Merck KGaA also received approval for ERBITUX in Argentina and
Mexico for use in combination with irinotecan or as a single agent in patients
with EGFR-expressing metastatic colorectal cancer after failure of
irinotecan-including cytotoxic therapy.

ERBITUX Important Safety Information

Severe infusion reactions, rarely fatal and characterized by rapid onset of
airway obstruction (bronchospasm, stridor, hoarseness), urticaria, and
hypotension, have occurred (3%) with the administration of ERBITUX. Most
reactions (90%) are associated with the first infusion of ERBITUX despite the
use of prophylactic antihistamines.

Severe cases of interstitial lung disease (ILD), which was fatal in one case,
occurred in less than 0.5% of patients receiving ERBITUX.

Dermatologic toxicities, including acneform rash (12% grade 3-4), skin drying
and fissuring, and inflammatory or infectious sequelae (e.g. blepharitis,
cheilitis, cellulitis, cyst) were reported. Sun exposure may exacerbate these
effects.

Other serious adverse events associated with ERBITUX in clinical trials were
fever (5%), sepsis (3%), kidney failure (2%), pulmonary embolus (1%),
dehydration (5% in patients receiving ERBITUX plus irinotecan, 2% receiving
monotherapy) and diarrhea (6% in patients receiving ERBITUX plus irinotecan, 0%
with monotherapy).

Additional common adverse events seen in patients receiving ERBITUX plus
irinotecan (n=354) or ERBITUX monotherapy (n=279) were acneform rash (88%/90%),
asthenia/malaise (73%/49%), diarrhea (72%/28%), nausea (55%/29%), abdominal pain
(45%/25%), vomiting (41%/25%), fever (34%/33%) and constipation (30%/28%).

Full prescribing information is available upon request, or at
www.ERBITUX.com.

Background Information

ERBITUX binds specifically to epidermal growth factor receptor (EGFR, HER1,
c-ErbB-1) on both normal and tumor cells, and competitively inhibits the binding
of epidermal growth factor (EGF) and other ligands, such as transforming growth
factor-alpha. The EGFR is constitutively expressed in many normal epithelial
tissues, including the skin and hair follicle. Over- expression of EGFR is also
detected in many human cancers including those of the colon and rectum.

According to the American Cancer Society, approximately 40,000 Americans will be
diagnosed with oral, head and neck cancer this year, including cancers of the
tongue, mouth, pharynx, and larynx. More than 11,000 will die from the disease
in 2004. Approximately 70,000 new cases are diagnosed annually in Europe, with
more than 25,000 deaths each year. Treatment for head and neck cancer may
include surgery, radiation therapy and chemotherapy or some combination of
these.

About ImClone Systems Incorporated

ImClone Systems Incorporated is committed to advancing oncology care by
developing and commercializing a portfolio of targeted biologic treatments
designed to address the medical needs of patients with a variety of cancers. The
Company's three programs include growth factor blockers, angiogenesis inhibitors
and cancer vaccines. ImClone Systems' strategy is to become a fully integrated
biopharmaceutical company, taking its development programs from the research
stage to the market. ImClone Systems' headquarters and research operations are
located in New York City, with additional administration and manufacturing
facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute forward- looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995 and the Federal securities laws. Although the company believes that the
expectations reflected in such forward-looking statements are based upon
reasonable assumptions it can give no assurance that its expectations will be
achieved. Forward-looking information is subject to certain risks, trends and
uncertainties that could cause actual results to differ materially from those
projected. Many of these factors are beyond the company's ability to control or
predict. Important factors that may cause actual results to differ materially
and could impact the company and the statements contained in this news release
can be found in the company's filings with the Securities and Exchange
Commission including quarterly reports on Form 10-Q, current reports on Form 8-K
and annual reports on Form 10-K. For forward-looking statements in this news
release, the company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation Reform
Act of 1995. The company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information, future events
or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive
exploration of innovative cancer fighting therapies designed to extend and
enhance the lives of patients living with cancer. More than 40 years ago,
Bristol-Myers Squibb built a unified vision for the future of cancer treatment.
With expertise, dedication and resolve, that vision led to the development of a
diverse global portfolio of anti-cancer therapies that are an important
cornerstone of care today. Hundreds of scientists at Bristol-Myers Squibb's
Pharmaceutical Research Institute are studying ways to improve current cancer
treatments and identify better, more effective medicines for the future.

Bristol-Myers Squibb is a global pharmaceutical and related health care products
company whose mission is to extend and enhance human life.

This press release contains "forward-looking statements" as that term is defined
in the Private Securities Litigation Reform Act of 1995 regarding product
development. Such forward-looking statements are based on current expectations
and involve inherent risks and uncertainties, including factors that could
delay, divert or change any of them, and could cause actual outcomes and results
to differ materially from current expectations. No forward-looking statement can
be guaranteed. Forward-looking statements in this press release should be
evaluated together with the many uncertainties that affect Bristol-Myers
Squibb's business, particularly those identified in the cautionary factors
discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year
ended December 31, 2003 and in our Quarterly Reports on Form 10-Q. Bristol-Myers
Squibb undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a global pharmaceutical and chemical company
with sales of EUR 7.2 billion in 2003, a history that began in 1668, and a
future shaped by 28,300 employees in 56 countries. Its success is characterized
by innovations from entrepreneurial employees. Merck's operating activities come
under the umbrella of Merck KGaA, in which the Merck family holds a 74 percent
interest and free shareholders own the remaining 26 percent. The former U.S.
subsidiary, Merck & Co., has been completely independent of the Merck Group
since 1917.

Merck KGaA, Darmstadt, Germany, licensed the right to market ERBITUX outside the
U.S. and Canada from ImClone Systems Incorporated of New York in 1998. In Japan,
Merck KGaA has co-exclusive marketing rights with ImClone Systems.

Notes to editors:

Data from EMR-008 (Abstract 5513) were presented Sunday, June 6, 1:00 PM CDT
during a poster discussion session on head and neck cancer.

Data from EMR-016 (Abstract 5502) were presented Tuesday, June 8, 10:45 AM CDT
during an oral presentation session on head and neck cancer.

SOURCE ImClone Systems Incorporated; Merck KGaA; Bristol-Myers Squibb Company



CONTACT:          Andrea Rabney, Corporate Communications, +1-646-638-5058,

                 Andrea.Rabney@imclone.com, or David Pitts, Corporate Communications

                 +1-646-638-5058, David.Pitts@imclone.com, or Stefania Bethlen, Corporate

                 Communications, IR, +1-646-638-5058, Stefania.Bethlen@imclone.com, all of

                 ImClone Systems Incorporated; Tracy Furey, Corporate Affairs, +1-609-252-3208,

                 Tracy.Furey@bms.com, or Susan Walser, Investor Relations, +1-212-546-4631,

                 Susan.walser@bms.com, or John Elicker, Investor Relations, +1-212-546-3775,

                 john.elicker@bms.com, or Kathy Baum, Corporate Affairs, +1-609-252-4227,

                 Kathy.Baum@bms.com, all of Bristol-Myers Squibb; or Phyllis Carter, Corporate

                 Media Relations, Merck KGaA, +49-6151-72-7144, Phyllis.Carter@merck.de



URL:              www.ERBITUX.com

http://www.ariva.de/opt/searchos/...uzeit=0&max_laufzeit=182&go=Go%21

Nur leider haben die alle einen Wahnsinns Spread 600 bis 2000 % , das darf doch nicht wahr sein!

http://www.ariva.de/opt/searchos/...eit=182&max_laufzeit=365&go=Go%21

Bei höherem Basis Preis ist der Spread niedriger!

Dürfte trotzdem nicht sein!
Hier ist der Willkür Tür und Tor geöffnet!

Vielleicht ist der Kurs auch nciht akktuell von Ariva!
gruß
gs

irgendwelche ideen ? über morgen soll ja pressekonferenz zu den neuen zahlen sein, sind die eventuell schon raus (und schlecht) ? habe nix gefunden..

discount on Martha Stewart Everyday brand bed and bath products. It declined to
say whether the sale was connected with her sentencing.

It was Stewart's 2001 ImClone stock sale -- and her actions afterward -- that
led to her downfall.

In December 2001, ImClone was riding high. The biotech company had recently
inked a $2 billion investment and marketing deal with pharmaceutical giant
Bristol-Myers Squibb. ImClone's flagship cancer drug, Erbitux, was awaiting
approval from the U.S. Food and Drug Administration.

But while the drug showed promise, ImClone's supporting studies were flawed.

The day after Christmas, ImClone founder and Stewart friend, Samuel D. Waksal
learned that the FDA would refuse to review the company's application to sell
Erbitux in the United States due to a badly designed clinical trial and poor
data.

Waksal unsuccessfully tried to dump ImClone shares on Dec. 27, but tipped off
two family members who sold $10.5 million of the stock. Waksal is currently
serving a seven-year sentence after pleading guilty to securities fraud and
other charges.

Stewart also sold her ImClone shares on Dec. 27.

After the markets closed the following day, ImClone publicly revealed problems
with the Erbitux application. The next trading day, the stock price plunged 16
percent to $46.46. It was New Year's Eve.

Such price volatility is common for stock in biotechnology companies with only
one or two potential products, said Brian D. Rye, an analyst with Janney
Montgomery Scott in Philadelphia who follows the sector.

"It really is unpredictable," Rye said. "You can handicap it a little bit, but
at the end of the day, there really are no assurances until you get a drug
approval from the FDA."

Rye said "Erbitux has the potential to become a blockbuster drug" with more than
$1 billion in annual sales.

ImClone's stock cratered after the FDA's 2001 rejection of Erbitux. Shares fell
to $6.11 on Sept. 23, 2002 from a high of $73.83 nine and a half months earlier.

Just as Stewart was indicted in June 2003, ImClone's stock began to rebound
following the release of a better-designed study showing that 23 percent of
patients who took Erbitux in combination with another chemotherapy drug
responded to the treatment.

The day after Stewart was charged, ImClone and Bristol-Myers announced they
would use the new data and resubmit Erbitux to the FDA later that year.

The drug was approved for sale by the FDA for use in patients in February.

"Erbitux is clearly a valuable tool to help treat patients with advanced cancers
of the colon and rectum," said Louis M. Weiner chairman of the department of
medical oncology at Fox Chase Cancer Center in Philadelphia. "It has previously
been shown and continues to demonstrate important anticancer activity in people
whose cancers have stopped responding to the conventional chemotherapy."

Weiner said given the large numbers of patients with such cancers, the potential
market for Erbitux and similar drugs is enormous. And the drug could be found
helpful in treating other cancers or colorectal cancer at earlier stages, he
added.


By Josh Goldstein

To see more of The Philadelphia Inquirer, or to subscribe to the newspaper, go
to www.philly.com.


(c) 2004, The Philadelphia Inquirer. Distributed by Knight Ridder/Tribune
Business News. For information on republishing this content, contact us at (800)
661-2511 (U.S.), (213) 237-4914 (worldwide), fax (213) 237-6515, or e-mail
reprints@krtinfo.com.

Martha Stewart gets 5 months behind bars  


NEW YORK, Jul 16, 2004 (United Press International via COMTEX) -- Martha
Stewart was sentenced Friday in New York to five months in prison and five
months of house arrest for lying about a stock sale in late 2001.

The sentence, which also included a $30,000 fine, by U.S. District Court judge
Miriam Goldman Cedarbaum follows Stewart's March 5 conviction for obstructing
justice, conspiracy and making false statements in the sale of ImClone Systems
stock, ABC News reported.

Cedarbaum also sentenced Stewart, 62, to two years' probation.

Stewart's lawyers said they would appeal, and the judge stayed her sentence
until the appeal could be heard.

Moments after the sentence Stewart emerged from the courthouse defiant.

"This is a shameful day, it is shameful for me, it is shameful for my family and
it is shameful for my beloved company," Stewart said. "What was a small personal
matter has become over the last two years an almost fatal circus event of
unprecedented proportions ... and with such venom and such gore."

"I will be back. I am not afraid."

Cederbaum had the option to lock Stewart up for longer or just give her parole.

Cedarbaum was expected to sentence Stewart's stockbroker, former Merrill Lynch
trader Peter Bacanovic, later Friday.




Copyright 2004 by United Press International.

die sache ist uralt, und das urteil hat dazu geführt, dass ihre eigene aktie durch die decke geknallt ist.
daran kanns also kaum liegen...
ach ja, sie hatte 3928 stück aktien von imclone..
der insider-skandal selbst ist ja rund 1 jahr her. damals ist die aktie deswegen eingeknickt. aber heute, 2 tage vor den zahlen ?
isch waaass netttt....
na ja, hab mal aufgestockt (GS8PWT)

@fluxx?

Ich bin in meinem Call auch drin geblieben!

However, an appeal could upset and prolong that, and the company could again
flounder, leaving her supporters with an understanding that Martha Stewart is
still thinking only about Martha Stewart, who had reminded the court of "all
the good I've done."

Meanwhile, Kmart Holding Corp. (NASDAQ: KMRT) said "Martha Stewart Living
Omnimedia is a valued brand partner of Kmart," adding that "we look forward to
continuing our mutually beneficial and successful relationship with MSLO."

For up-to-the-minute news, features and links click on
www.financialwire.net

FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press
release service and receives no compensation for its news or opinions. Other
divisions of Investrend, however, provide shareholder empowerment platforms such
as forums, independent research and webcasting. For more information or to
receive the FirstAlert daily summary of news, commentary, research reports,
webcasts, events and conference calls, click on
www.investrend.com/contact.asp

The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: www.investrend.com/XmlFeeds?level=268



URL:              www.financialwire.net


(C) 2004 financialwire.net,  Inc. All rights reserved.

von gestern 0,35 (wenn goldman nicht wieder mal in der heissesten phase das buch gesperrt hätte, wären rechnerisch 0,28 als kaufkurs drin gewesen!) auf jetzt 0,51 geld.

die stücke von gestern wieder verkauft, andere hälfte noch behalten.
hach, börse kann manchmal so einfach sein..
:-))

innerhalb etwas mehr als 1 tag verliere ich bisschen den mut. auch der chart zeigt einen widerstand bei um die 80 $.
die aktie ist klasse, aber eben auch sehr volatil. verkaufe jetzt sicherheitshalber auch den rest (im mom 60-62).
und hoffe dann, dass die aktie noch mal runterkommt bevor sie auf über 100 $ geht, damit ich wieder rein kann ..
gruss @ geldschneider, lief doch ziemlich gut !!

Bei Imclone habe ich viel verloren an Gewinn, weil ich jedesm al beim down raus ging.

Den richtigen Einstieg dann verpasst, nun lasse ich den Call laufen!

Oh mein Gott, Goldman Sachs hatte wieder techn. prbleme, weilder Kurs so hoch stieg?

also ich handle jetzt nur mehr ami Optionen bei ami Werten.

Weil mir das auf und ab nach Deutscher Börse, dann Ami Börse zu dumm ist, und zu willkürlich ist.

gruß
gs

statt fair zu sein und preise zu stellen auch wenns in der basis-aktie rund geht, sperren sie halt das buch und warten bisschen ab. nicht sonderlich professionell !!
gestern als die aktie kurz so runterging, haben sie bei 30-32 "eingefroren", 26-28 gar nicht erst gepreist (aktie fiel noch 1 $ weiter), und erst wieder aufgemacht als 33-35 war. saftladen !!
vom prinzip hast du recht, die aktie ist klasse und wird weitersteigen. aber fürs abwarten bin ICH zu nervös.. und ums echt langfristig zu sehen ist die implizite vola (und damit das aufgeld der option) von über 50 bei 2 und 5 monats-optionen einfach bisschen hoch..
ich hoffe halt auf noch einen dip nach unten. auch wenns heute zahlen gibt, die bestimmt prima sein werden.
gruss und viel glück